Search

Your search keyword '"Capobianco, Daniela"' showing total 25 results
Start Over Author "Capobianco, Daniela" Publication Year Range Last 10 years
25 results on '"Capobianco, Daniela"'

7. Euclid Preparation. XIV. The Complete Calibration of the Color-Redshift Relation (C3R2) Survey:Data Release 3

Author

Stanford, S. A., Masters, D., Darvish, B., Stern, D., Cohen, J. G., Capak, P., Hernitschek, N., Davidzon, I., Rhodes, J., Sanders, D. B., Mobasher, B., Castander, F. J., Paltani, S., Aghanim, N., Amara, A., Auricchio, N., Balestra, A., Bender, R., Bodendorf, C., Bonino, D., Branchini, E., Brinchmann, J., Capobianco, Daniela, Carbone, C., Carretero, J., Casas, R., Castellano, M., Cavuoti, S., Cimatti, A., Cledassou, R., Conselice, C. J., Corcione, L., Costille, A., Cropper, M., Degaudenzi, H., Douspis, M., Dubath, F., Dusini, S., Fosalba, P., Frailis, M., Franceschi, E., Franzetti, P., Fumana, M., Garilli, B., Giocoli, C., Grupp, F., Haugan, S. V. H., Hoekstra, H., Holmes, W., Hormuth, F., Hudelot, P., Jahnke, K., Kiessling, A., Kilbinger, M., Kitching, T., Kubik, B., Kuemmel, M., Kunz, M., Kurki-Suonio, H., Laureijs, R., Ligori, S., Lilje, P. B., Lloro, Ivan, Maiorano, E., Marggraf, O., Markovic, K., Massey, R., Meneghetti, M., Meylan, G., Moscardini, L., Niemi, S. M., Padilla, C., Pasian, F., Pedersen, K., Pettorino, V., Pires, S., Poncet, M., Popa, L., Pozzetti, L., Raison, F., Roncarelli, M., Rossetti, E., Saglia, R., Scaramella, R., Schneider, P., Secroun, A., Seidel, G., Serrano, S., Sirignano, C., Sirri, G., Taylor, A. N., Teplitz, H., Tereno, Toledo-Moreo, R., Valentijn, A., Valenziano, L., Verdoeskleijn, G. A., Wang, Y., Zamorani, G., Zoubian, J., Brescia, M., Congedo, G., Conversi, L., Copin, Y., Kermiche, S., Kohley, R., Medinaceli, E., Mei, S., Moresco, M., Morin, B., Munari, E., Polenta, G., Sureau, F., Vassallo, T., Zacchei, A., Andreon, S., Aussel, H., Baccigalupi, C., Balaguera-Antolinez, A., Baldi, M., Bardelli, S., Biviano, A., Borsato, E., Bozzo, E., Burigana, C., Cabanac, R., Camera, S., Cappi, A., Carvalho, C. S., Casas, S., Castignani, G., Colodro-Conde, C., Coupon, J., Courtois, H. M., Cuby, J-G, Dasilva, A., De Latorre, S., Diferdinando, D., Duncan, C. A. J., Dupac, X., Fabricius, M., Farina, M., Farrens, S., Ferreira, P. G., Finelli, F., Flose-Reimberg, P., Fotopoulou, S., Galeotta, S., Ganga, K., Gillard, W., Gozaliasl, G., Gracia-Carpio, J., Keihanen, E., Kirkpatrick, C. C., Lindholm, Ulrika, Mainetti, G., Maino, D., Martinet, N., Marulli, F., Maturi, M., Maurogordato, S., Metcalf, R. B., Nakajima, R., Neissner, C., Nightingale, J. W., Nucita, A. A., Patrizii, L., Potter, D., Renzi, A., Riccio, G., Romelli, E., Sanchez, A. G., Sapone, D., Schirmer, M., Schultheis, M., Scottez, V., Stanco, L., Tenti, M., Teyssier, R., Torradeflot, F., Valiviita, J., Viel, M., Whittaker, L., Zucca, E., Stanford, S. A., Masters, D., Darvish, B., Stern, D., Cohen, J. G., Capak, P., Hernitschek, N., Davidzon, I., Rhodes, J., Sanders, D. B., Mobasher, B., Castander, F. J., Paltani, S., Aghanim, N., Amara, A., Auricchio, N., Balestra, A., Bender, R., Bodendorf, C., Bonino, D., Branchini, E., Brinchmann, J., Capobianco, Daniela, Carbone, C., Carretero, J., Casas, R., Castellano, M., Cavuoti, S., Cimatti, A., Cledassou, R., Conselice, C. J., Corcione, L., Costille, A., Cropper, M., Degaudenzi, H., Douspis, M., Dubath, F., Dusini, S., Fosalba, P., Frailis, M., Franceschi, E., Franzetti, P., Fumana, M., Garilli, B., Giocoli, C., Grupp, F., Haugan, S. V. H., Hoekstra, H., Holmes, W., Hormuth, F., Hudelot, P., Jahnke, K., Kiessling, A., Kilbinger, M., Kitching, T., Kubik, B., Kuemmel, M., Kunz, M., Kurki-Suonio, H., Laureijs, R., Ligori, S., Lilje, P. B., Lloro, Ivan, Maiorano, E., Marggraf, O., Markovic, K., Massey, R., Meneghetti, M., Meylan, G., Moscardini, L., Niemi, S. M., Padilla, C., Pasian, F., Pedersen, K., Pettorino, V., Pires, S., Poncet, M., Popa, L., Pozzetti, L., Raison, F., Roncarelli, M., Rossetti, E., Saglia, R., Scaramella, R., Schneider, P., Secroun, A., Seidel, G., Serrano, S., Sirignano, C., Sirri, G., Taylor, A. N., Teplitz, H., Tereno, Toledo-Moreo, R., Valentijn, A., Valenziano, L., Verdoeskleijn, G. A., Wang, Y., Zamorani, G., Zoubian, J., Brescia, M., Congedo, G., Conversi, L., Copin, Y., Kermiche, S., Kohley, R., Medinaceli, E., Mei, S., Moresco, M., Morin, B., Munari, E., Polenta, G., Sureau, F., Vassallo, T., Zacchei, A., Andreon, S., Aussel, H., Baccigalupi, C., Balaguera-Antolinez, A., Baldi, M., Bardelli, S., Biviano, A., Borsato, E., Bozzo, E., Burigana, C., Cabanac, R., Camera, S., Cappi, A., Carvalho, C. S., Casas, S., Castignani, G., Colodro-Conde, C., Coupon, J., Courtois, H. M., Cuby, J-G, Dasilva, A., De Latorre, S., Diferdinando, D., Duncan, C. A. J., Dupac, X., Fabricius, M., Farina, M., Farrens, S., Ferreira, P. G., Finelli, F., Flose-Reimberg, P., Fotopoulou, S., Galeotta, S., Ganga, K., Gillard, W., Gozaliasl, G., Gracia-Carpio, J., Keihanen, E., Kirkpatrick, C. C., Lindholm, Ulrika, Mainetti, G., Maino, D., Martinet, N., Marulli, F., Maturi, M., Maurogordato, S., Metcalf, R. B., Nakajima, R., Neissner, C., Nightingale, J. W., Nucita, A. A., Patrizii, L., Potter, D., Renzi, A., Riccio, G., Romelli, E., Sanchez, A. G., Sapone, D., Schirmer, M., Schultheis, M., Scottez, V., Stanco, L., Tenti, M., Teyssier, R., Torradeflot, F., Valiviita, J., Viel, M., Whittaker, L., and Zucca, E.

Abstract

The Complete Calibration of the Color-Redshift Relation (C3R2) survey is obtaining spectroscopic redshifts in order to map the relation between galaxy color and redshift to a depth of i similar to 24.5 (AB). The primary goal is to enable sufficiently accurate photometric redshifts for Stage iv dark energy projects, particularly Euclid and the Nancy Grace Roman Space Telescope (Roman), which are designed to constrain cosmological parameters through weak lensing. We present 676 new high-confidence spectroscopic redshifts obtained by the C3R2 survey in the 2017B-2019B semesters using the DEIMOS, LRIS, and MOSFIRE multiobject spectrographs on the Keck telescopes. Combined with the 4454 redshifts previously published by this project, the C3R2 survey has now obtained and published 5130 high-quality galaxy spectra and redshifts. If we restrict consideration to only the 0.2 < z ( p ) < 2.6 range of interest for the Euclid cosmological goals, then with the current data release, C3R2 has increased the spectroscopic redshift coverage of the Euclid color space from 51% (as reported by Masters et al.) to the current 91%. Once completed and combined with extensive data collected by other spectroscopic surveys, C3R2 should provide the spectroscopic calibration set needed to enable photometric redshifts to meet the cosmology requirements for Euclid, and make significant headway toward solving the problem for Roman.

Published
2021

9. Euclid preparation VIII. The Complete Calibration of the Colour-Redshift Relation survey:VLT/KMOS observations and data release

Author

Guglielmo, Saglia, R., Castander, F. J., Galametz, A., Paltani, S., Bender, R., Bolzonella, M., Capak, P., Ilbert, O., Masters, D. C., Stern, D., Andreon, S., Auricchio, N., Balaguera-Antolinez, A., Baldi, M., Bardelli, S., Biviano, A., Bodendorf, C., Bonino, D., Bozzo, E., Branchini, E., Brau-Nogue, S., Brescia, M., Burigana, C., Cabanac, R. A., Camera, S., Capobianco, Daniela, Cappi, A., Carbone, C., Carretero, J., Carvalho, C. S., Casas, R., Casas, S., Castellano, M., Castignani, G., Cavuoti, S., Cimatti, A., Cledassou, R., Colodro-Conde, C., Congedo, G., Conselice, C. J., Conversi, L., Copin, Y., Corcione, L., Costille, A., Coupon, J., Courtois, H. M., Cropper, M., Da Silva, A., de la Torre, S., Guglielmo, Saglia, R., Castander, F. J., Galametz, A., Paltani, S., Bender, R., Bolzonella, M., Capak, P., Ilbert, O., Masters, D. C., Stern, D., Andreon, S., Auricchio, N., Balaguera-Antolinez, A., Baldi, M., Bardelli, S., Biviano, A., Bodendorf, C., Bonino, D., Bozzo, E., Branchini, E., Brau-Nogue, S., Brescia, M., Burigana, C., Cabanac, R. A., Camera, S., Capobianco, Daniela, Cappi, A., Carbone, C., Carretero, J., Carvalho, C. S., Casas, R., Casas, S., Castellano, M., Castignani, G., Cavuoti, S., Cimatti, A., Cledassou, R., Colodro-Conde, C., Congedo, G., Conselice, C. J., Conversi, L., Copin, Y., Corcione, L., Costille, A., Coupon, J., Courtois, H. M., Cropper, M., Da Silva, A., and de la Torre, S.

Abstract

The Complete Calibration of the Colour-Redshift Relation survey (C3R2) is a spectroscopic e ffort involving ESO and Keck facilities designed specifically to empirically calibrate the galaxy colour-redshift relation - P(z jC) to the Euclid depth (iAB = 24 :5) and is intimately linked to the success of upcoming Stage IV dark energy missions based on weak lensing cosmology. The aim is to build a spectroscopic calibration sample that is as representative as possible of the galaxies of the Euclid weak lensing sample. In order to minimise the number of spectroscopic observations necessary to fill the gaps in current knowledge of the P(z jC), self-organising map (SOM) representations of the galaxy colour space have been constructed. Here we present the first results of an ESO@VLT Large Programme approved in the context of C3R2, which makes use of the two VLT optical and near-infrared multi-object spectrographs, FORS2 and KMOS. This data release paper focuses on high-quality spectroscopic redshifts of high-redshift galaxies observed with the KMOS spectrograph in the near-infrared H- and K-bands. A total of 424 highly-reliable redshifts are measured in the 1:3 2 galaxies.

Published
2020

13. Effectiveness and Safety of a Probiotic-Mixture for the Treatment of Infantile Colic: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial with Fecal Real-Time PCR and NMR-Based Metabolomics Analysis

Author

Baldassarre, Maria, primary, Di Mauro, Antonio, additional, Tafuri, Silvio, additional, Rizzo, Valentina, additional, Gallone, Maria, additional, Mastromarino, Paola, additional, Capobianco, Daniela, additional, Laghi, Luca, additional, Zhu, Chenglin, additional, Capozza, Manuela, additional, and Laforgia, Nicola, additional

Published
2018
Full Text
View/download PDF

16. Fecal Microbiota, Fecal and Urinary Metabolic Profiling and Symptomatic Uncomplicated Diverticular Disease of the Colon

Author

Tursi, Antonio, primary, Mastromarino, Paola, additional, Capobianco, Daniela, additional, Elisei, Walter, additional, Miccheli, Alfredo, additional, Capuani, Giorgio, additional, Praticò, Giulia, additional, Picchio, Marcello, additional, Giorgetti, GianMarco, additional, Mario, Francesco Di, additional, and Brandimarte, Giovanni, additional

Published
2017
Full Text
View/download PDF

19. Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial

Author

Baldassarre, Maria, primary, Di Mauro, Antonio, additional, Mastromarino, Paola, additional, Fanelli, Margherita, additional, Martinelli, Domenico, additional, Urbano, Flavia, additional, Capobianco, Daniela, additional, and Laforgia, Nicola, additional

Published
2016
Full Text
View/download PDF

20. Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon

Author

Tursi, Antonio, primary, Mastromarino, Paola, additional, Capobianco, Daniela, additional, Elisei, Walter, additional, Miccheli, Alfredo, additional, Capuani, Giorgio, additional, Tomassini, Alberta, additional, Campagna, Giuseppe, additional, Picchio, Marcello, additional, Giorgetti, GianMarco, additional, Fabiocchi, Federica, additional, and Brandimarte, Giovanni, additional

Published
2016
Full Text
View/download PDF

24. Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: A double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-Based metabolomics analysis

Author

Paola Mastromarino, Nicola Laforgia, Luca Laghi, Silvio Tafuri, Antonio Di Mauro, Valentina Rizzo, Daniela Capobianco, Maria Elisabetta Baldassarre, Maria Serena Gallone, Chenglin Zhu, Manuela Capozza, Baldassarre, Maria Elisabetta, Di Mauro, Antonio, Tafuri, Silvio, Rizzo, Valentina, Gallone, Maria Serena, Mastromarino, Paola, Capobianco, Daniela, Laghi, Luca, Zhu, Chenglin, Capozza, Manuela, and Laforgia, Nicola

Subjects
Male, Parents, medicine.medical_specialty, Colic, Visual analogue scale, Metabolomic, Crying, Real-Time Polymerase Chain Reaction, Placebo, Probiotic, Gastroenterology, Article, Infantile colic, Feces, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, 030225 pediatrics, Internal medicine, medicine, Humans, Adverse effect, infantile colic, probiotics, metabolomics, microbiota, Nutrition and Dietetics, business.industry, Probiotics, Microbiota, Infant, Newborn, Infant, medicine.disease, Magnetic Resonance Imaging, Clinical trial, Breast Feeding, Treatment Outcome, Quality of Life, Defecation, Female, 030211 gastroenterology & hepatology, medicine.symptom, business, Food Science
Abstract

Introduction: To investigate the effectiveness and the safety of a probiotic-mixture (Vivomixx®, Visbiome®, DeSimone Formulation®; Danisco-DuPont, Madison, WI, USA) for the treatment of infantile colic in breastfed infants, compared with a placebo. Methods: A randomized, double-blind, placebo-controlled trial was conducted in exclusively breastfed infants with colic, randomly assigned to receive a probiotic-mixture or a placebo for 21 days. A structured diary of gastrointestinal events of the infants was given to the parents to complete. Samples of feces were also collected to evaluate microbial content and metabolome using fecal real-time polymerase chain reaction (qPCR) and Nuclear magnetic resonance (NMR)-based analysis. Study registered at ClinicalTrials.gov (NCT01869426). Results: Fifty-three exclusively-breastfed infants completed three weeks of treatment with a probiotic-mixture (n = 27) or a placebo (n = 26). Infants receiving the probiotic-mixture had less minutes of crying per day throughout the study by the end of treatment period (68.4 min/day vs. 98.7 min/day; p = 0.001). A higher rate of infants from the probiotic-mixture group responded to treatment (defined by reduction of crying times of ≥50% from baseline), on day 14, 12 vs. 5 (p = 0.04) and on day 21, 26 vs. 17 (p = 0.001). A higher quality of life, assessed by a 10-cm visual analogue scale, was reported by parents of the probiotic-mixture group on day 14, 7.1 ± 1.2 vs. 7.7 ± 0.9 (p = 0.02); and on day 21, 6.7 ± 1.6 vs. 5.9 ± 1.0 (p = 0.001). No differences between groups were found regarding anthropometric data, bowel movements, stool consistency or microbiota composition. Probiotics were found to affect the fecal molecular profile. No adverse events were reported. Conclusions: Administration of a probiotic-mixture appears safe and reduces inconsolable crying in exclusively breastfed infants.

Published
2018

25. Efficacy and safety of a multistrain probiotic formulation depends from manufacturing

Author

Paola Mastromarino, Luca Laghi, Beatrice Vitali, Claudio De Simone, Ilaria Giusti, Daniela Capobianco, Carola Eleonora Parolin, Vito Trinchieri, Trinchieri, Vito, Laghi, Luca, Vitali, Beatrice, Parolin, CAROLA ELEONORA, Giusti, Ilaria, Capobianco, Daniela, Mastromarino, Paola, and De Simone, Claudio

Subjects
lcsh:Immunologic diseases. Allergy, 0301 basic medicine, Metabolite, Immunology, Biology, Pharmacology, medicine.disease_cause, law.invention, Microbiology, 03 medical and health sciences, Probiotic, chemistry.chemical_compound, 0302 clinical medicine, law, microbiota, medicine, Metabolome, Immunology and Allergy, Viability assay, Hepatic encephalopathy, Feces, Original Research, human immunodeficiency virus, human immunodeficiency viru, VSL#3, medicine.disease, biology.organism_classification, metabolomics, 030104 developmental biology, probiotics, chemistry, 030220 oncology & carcinogenesis, gut, lcsh:RC581-607, Staphylococcus, probiotic, Bacteria, metabolomic
Abstract

Background: Variability in probiotics manufacturing may affect their properties, with potential implications for their efficacy and safety. This is of particular concern with probiotic products destined for use in patients with serious medical conditions, including human immunodeficiency virus (HIV) infection. The purpose of the study was to carry out a series of experiments comparing the properties of the US-made probiotic formulation originally commercialized under the brand name VSL#3®, with those of the Italian-made formulation now commercialized under the same name. The US-made formulation has previously shown beneficial effects at the intestinal and neurological levels in HIV-infected subjects as well as in patients with inflammatory bowel diseases and hepatic encephalopathy. Methods: Eleven subjects receiving combined antiretroviral therapy for HIV-1 were treated for 6 months with the US-made VSL#3 formulation. At baseline and 6 months, T-cells were analyzed for phenotype and activation markers, and fecal samples were analyzed for bifidobacteria, lactobacilli, and their metabolites. The fecal metabolome was assessed using 1H-NMR spectroscopy. Production of metabolites of interest by bacteria obtained from sachets of the two formulations was compared in vitro and their effects on a rat intestinal epithelial cell line (IEC-6) were assessed. Particular attention was paid to the metabolite 1,3-dihydroxyacetone (DHA). Results: At 6 months, fecal samples showed a significant increase in the specific bacterial genera contained in the probiotic supplement. Immune activation was reduced as shown by a significant reduction in the percentage of CD4+CD38+HLA-DR+ T-cells at 6 months. Fecal concentrations of DHA decreased significantly. In vitro, significant differences in the production and metabolism of DHA were found between bacteria from the US-made and Italian-made formulations: the US-made formulation was able to metabolize DHA whereas the bacteria in the Italian-made formulation were producing DHA. DHA reduced the viability of Streptococcus thermophilus, reduced IEC-6 cell viability in a dose-dependent manner, and also led to a lower rate of repair to scratched IEC-6 cell monolayer. Conclusion: Our data, in conjunction with previously published findings, confirm that the new Italian-made formulation of VSL#3® is different from the previous US-made VSL#3 and therefore its efficacy and safety in HIV-infected subjects is still unproven.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results